We are live on ! Find out more
GHDX

Genomic Health, Inc.
GHDX

Delisted

GHDX was delisted on the 7th of November, 2019.

Back to rankings

0 hedge funds and large institutions have $0 invested in Genomic Health, Inc. in 2019 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 219 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 221 → 0 (-221)

100% less funds holding in top 10

Funds holding in top 10: 3 → 0 (-3)

100% less capital invested

Capital invested by funds: $2.44B → $0 (-$2.44B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 219

Holders
–
Holders Change
-221
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
219
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
-$627M
2
BlackRock
BlackRock
New York
-$276M
3
Vanguard Group
Vanguard Group
Pennsylvania
-$187M
4
Renaissance Technologies
Renaissance Technologies
New York
-$170M
5
State Street
State Street
Massachusetts
-$98.2M
Name Holding Trade Value Shares
Change 		Change in
Stake
Two Sigma Investments
76
Two Sigma Investments
New York
– -$2.44M -36,012 Closed
Caisse de Depot et Placement du Quebec (CDPQ)
77
Caisse de Depot et Placement du Quebec (CDPQ)
Quebec, Canada
– -$2.44M -36,000 Closed
American Century Companies
78
American Century Companies
Missouri
– -$2.22M -32,676 Closed
Skandinaviska Enskilda Banken (SEB)
79
Skandinaviska Enskilda Banken (SEB)
Sweden
– -$2.21M -32,600 Closed
GH
80
GAM Holding
Switzerland
– -$2.11M -31,051 Closed
GF
81
Gabelli Funds
New York
– -$2.04M -30,099 Closed
EAM
82
Exane Asset Management
France
– -$2.03M -30,000 Closed
CIA
83
Capital Impact Advisors
Massachusetts
– -$1.96M -28,570 Closed
SEC
84
Seven Eight Capital
New York
– -$1.92M -28,298 Closed
HA
85
Havens Advisors
New York
– -$1.9M -28,000 Closed
Los Angeles Capital Management
86
Los Angeles Capital Management
California
– -$1.86M -27,391 Closed
UBS AM
87
UBS AM
Illinois
– -$1.82M -26,843 Closed
ASRS
88
Arizona State Retirement System
Arizona
– -$1.72M -25,401 Closed
PNC Financial Services Group
89
PNC Financial Services Group
Pennsylvania
– -$1.66M -24,549 Closed
AAM
90
Arabesque Asset Management
United Kingdom
– -$1.45M -21,300 Closed
AAM
91
Advisors Asset Management
Colorado
– -$1.41M -20,819 Closed
Comerica Bank
92
Comerica Bank
Texas
– -$1.38M -20,508 Closed
GCP
93
GSA Capital Partners
United Kingdom
– -$1.32M -19,460 Closed
AIG
94
American International Group
New York
– -$1.31M -19,389 Closed
HM
95
Harvest Management
New York
– -$1.25M -18,500 Closed
CS
96
Credit Suisse
Switzerland
– -$1.25M -18,435 Closed
Thrivent Financial for Lutherans
97
Thrivent Financial for Lutherans
Minnesota
– -$1.17M -17,171 Closed
Manulife (Manufacturers Life Insurance)
98
Manulife (Manufacturers Life Insurance)
Ontario, Canada
– -$1.16M -16,906 Closed
FDCDDQ
99
Federation des caisses Desjardins du Quebec
Quebec, Canada
– -$1.13M -16,728 Closed
SOADOR
100
State of Alaska Department of Revenue
Alaska
– -$1.13M -16,605 Closed
2 3
4
5 6

GHDX Hedge Fund Activity: Q4 2019 in Review

0 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Genomic Health, Inc. (GHDX) for Q4 2019, worth a combined $0 — down 100% from $2.44B a quarter earlier.

Sellers outnumbered buyers: 219 funds closed out of GHDX and 0 opened new positions — a net loss of 219 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $627M sold.

  • 0 institutional investors held Genomic Health, Inc. (GHDX) as of Q4 2019, down from 221 in Q3 2019.
  • Funds reported $0 of Genomic Health, Inc. stock for Q4 2019, down 100% quarter-over-quarter.
  • 0 funds opened new Genomic Health, Inc. positions in Q4 2019 and 219 closed out, a net change of -219 holders.
  • The largest Genomic Health, Inc. seller in Q4 2019 was Baker Bros. Advisors, an estimated $627M sold.

Based on aggregated 13F filings for Q4 2019.